Venezuela Hits Dr. Reddy’s Profit, But Indicators Brighter
This article was originally published in PharmAsia News
Executive Summary
Indian generic drug heavyweight Dr. Reddy’s quarterly net profit has tumbled nearly 90% on an exceptional charge involving a $65m write-down on receipts due from its Venezuelan subsidiary but improved financial performance indicators have cheered investors.